Journal of Medicinal Chemistry · 2009 · 123 citations · 27 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationStructure-activity RelationshipsBlood-brain Barrier PenetrationBlood-brain Barrier PharmacologyHit-to-lead OptimizationLead Compound DesignLead DiscoveryStructure-activity Relationship AnalysisAnticancer ActivityAnticancer ChemotherapyApoptosis InductionApoptosis Induction TherapeuticsBlood-tumor Barrier PenetrationChemical Structure-activity RelationshipsLead Compound OptimizationStructure - Activity Relationship Optimization
As a continuation of our structure-activity relationship (SAR) studies on 4-anilinoquinazolines as potent apoptosis inducers and to identify anticancer development candidates, we explored the replacement of the 2-Cl group in our lead compound 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (6b, EP128265, MPI-0441138) by other functional groups. This SAR study and lead optimization resulted in the identification of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine (6h, EP128495, MPC-6827) as an anticancer clinical candidate. Compound 6h was found to be a potent apoptosis inducer with EC(50) of 2 nM in our cell-based apoptosis induction assay. It also has excellent blood brain barrier penetration, and is highly efficacious in human MX-1 breast and other mouse xenograft cancer models.
27
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Jeremy N. Rich, David A. Reardon, Terry Peery et al. · Journal of Clinical Oncology · 2003 · 736 citations · Full text
Medicine, Oncology, Pharmacology +17
Sanjeev Shangary, Dongguang Qin, Donna McEachern et al. · Proceedings of the National Academy of Sciences · 2008 · 656 citations · Full text
Medicine, Oncology, Pharmacology +13
Targeting Tyrosine Kinases in Cancer: The Second Wave
José Baselga · Science · 2006 · 477 citations
Medicine, Oncology, Pharmacology +15
The New Era in Cancer Research
Harold Varmus · Science · 2006 · 306 citations
Medicine, Cancer Biology, Oncology +11